Molecular Diagnostics Markets

Product Code TRI00021
Publication Date July 2011
Publisher TriMark Publications
Product Type Report
Pages 335
ISBN Number not applicable
Change currency
PDF £2,150.00 €2,589 $3,400 BUY >
Order by fax
Ask a question about this product > Receive product alerts > Call now +44 20 7060 7474

Molecular Diagnostics Markets

The technologies that constitute molecular diagnostics--like first-generation amplification, DNA probes, fluorescent in situ hybridization (FISH), second-generation biochips and microfluidics, next-generation signal detection, biosensors, and molecular labels--are influencing the discovery of therapeutic molecules, the screening and diagnosis of patients, and the optimization of drug therapy. In the past few years, this rapidly evolving field has seen several fascinating developments. This TriMark Publications report describes the specific market segment of the in vitro diagnostics market known as molecular diagnostics and includes all of the generally accepted clinical analytical activities in use today. It examines the prevalent clinical-measurement devices, as well as their reagents and supplies as utilized in hospitals, clinics, large reference laboratories and doctor's offices. Diagnostic tests marketed primarily as over-the-counter are generally not included in this report, although there is inevitably some overlap. The main objectives of this analysis are: 1) identifying viable technology drivers through a comprehensive look at platform technologies for molecular diagnostics, including probe-based nucleic acid assays, microarrays and sequencing; 2) obtaining a complete understanding of the chief molecular diagnostics tests--i.e., predictive, screening, prognostic, monitoring, pharmacogenomic and theranostic--from their basic principles to their applications; 3) discovering feasible market opportunities by identifying high-growth applications in different clinical diagnostic areas and by focusing on expanding markets, such as communicable diseases, cardiology and oncology; and 4) focusing on global industry development through an in-depth analysis of the major world markets for molecular diagnostics, including growth forecasts.

Contents

  • 1. Overview
    • 1.1 Statement of Report
    • 1.2 About This Report
    • 1.3 Scope of the Report
    • 1.4 Objectives
    • 1.5 Methodology
    • 1.6 Executive Summary
  • 2. Introduction to Molecular Diagnostics and PCR Technology
    • 2.1 Introduction to Genomics and Its Opportunity
    • 2.2 Impact of the Human Genome Project on Molecular Diagnostics
    • 2.3 Key Considerations for Molecular Diagnostics
    • 2.4 Molecular Diagnostics in the Post-Genomic Era
    • 2.5 Advances in Molecular Diagnostics Technologies
    • 2.6 Genetic Variability and Disease
    • 2.7 Major Technology Platforms
      • 2.7.1 Gene-based Amplification Technologies
      • 2.7.2 Detection of Amplified Gene Products
      • 2.7.3 Target-based Gene Amplification
        • 2.7.3.1 Polymerase Chain Reaction (PCR)
        • 2.7.3.2 Real-Time PCR
        • 2.7.3.3 Nucleic Acid Sequence-based Amplification (NASBA)
      • 2.7.4 Probe-based Amplification
        • 2.7.4.1 Ligase Chain Reaction (LCR)
        • 2.7.4.2 Strand Displacement Amplification (SDA)
        • 2.7.4.3 QB-Replicase Amplified Probe Assay
      • 2.7.5 Signal-based Amplification
        • 2.7.5.1 Branched DNA (bDNA)
      • 2.7.6 Other Gene Amplification Technologies
        • 2.7.6.1 Immuno-PCR (IPCR)
        • 2.7.6.2 Bio-Barcode Amplification Assay (BCA)
        • 2.7.6.3 Hybrid Capture
      • 2.7.7 Next Generation Sequencing
    • 2.8 PCR Reagents for Clinical Diagnostics
  • 3. Nucleic Acid Test Applications
    • 3.1 Molecular Diagnostic Testing and Infectious Diseases
      • 3.1.1 Genomics Molecular Diagnostics Market
        • 3.1.1.1 Methods for DNA Detection and Gene Sequencing
        • 3.1.1.2 Products and Applications
        • 3.1.1.3 Oncology
      • 3.1.2 SNPs and Genes: Medical Utility (Clinical Applications)
        • 3.1.2.1 Clinical Application Initiatives
        • 3.1.2.2 Sampling of Affymetrix's Clinical Application Collaborations
    • 3.2 Infectious Disease Testing Using Molecular Diagnostics
      • 3.2.1 HIV
      • 3.2.2 Hepatitis Serologic Markers and Nucleic Acid Testing
        • 3.2.2.1 Hepatitis A Virus (HAV)
        • 3.2.2.2 Hepatitis B Virus (HBV)
        • 3.2.2.2.1 Hepatitis B Market Size
        • 3.2.2.3 Hepatitis C Virus (HCV)
        • 3.2.2.4 Hepatitis D Virus (HDV)
        • 3.2.2.5 Hepatitis E Virus (HEV)
      • 3.2.3 Human Papillomavirus (HPV)
      • 3.2.4 Influenza Viruses
        • 3.2.4.1 H5N1 Influenza Virus
        • 3.2.4.2 H1N1 Influenza Virus
      • 3.2.5 Cancer Detection Using Molecular Diagnostics
        • 3.2.5.1 Lung Cancer
        • 3.2.5.2 Oral Cancer
        • 3.2.5.3 Prostate Cancer
        • 3.2.5.3.1 PCA3
        • 3.2.5.3.2 Companies Active in Molecular Diagnostics and Prostate Cancer Analysis
        • 3.2.5.4 Chronic Myelogenous Leukemia
        • 3.2.5.5 Malignant Gliomas
        • 3.2.5.6 Colorectal Cancer
        • 3.2.5.6.1 Background on KRAS Mutation
        • 3.2.5.7 Breast Cancer
        • 3.2.5.8 Bladder Cancer
        • 3.2.5.9 Ovarian Cancer
        • 3.2.5.10 Molecular Diagnostic Screening Test for Cancer
        • 3.2.5.11 Cervical Cancer
      • 3.2.6 Microbiology Testing Using Molecular Diagnostics
        • 3.2.6.1 Chlamydia
        • 3.2.6.1.1 Revenue Forecasts
        • 3.2.6.2 Gonorrhea
        • 3.2.6.3 Tuberculosis (TB)
        • 3.2.6.4 Group B Streptococcus (GBS)
        • 3.2.6.5 Bordetella pertussis
        • 3.2.6.6 Legionella pneumophila
        • 3.2.6.7 Periodontal Bacteria
        • 3.2.6.8 Pneumocystis carinii
        • 3.2.6.9 Methicillin-resistant Staphylococcus Aureus (MRSA)
        • 3.2.6.10 Clostridium difficile
        • 3.2.6.11 Vancomycin-resistant Enterococci (VRE)
        • 3.2.6.12 Fungal Infections
        • 3.2.6.13 Herpes
        • 3.2.6.14 Other Infectious Diseases
      • 3.2.7 Blood Screening Using Molecular Diagnostics
        • 3.2.7.1 Blood Screening Competitive Positions
    • 3.3 Genetics Testing in Molecular Diagnostics
      • 3.3.1 Functional Genomics
      • 3.3.2 Genetic and Paternity Testing
    • 3.4 Molecular Diagnostics Uses in Industrial Testing and Food Diagnostics
      • 3.4.1 The Market
      • 3.4.2 Detection of Helicobacter pylori by PCR
      • 3.4.3 Detection of Escherichia coli 0157
      • 3.4.4 Detection of Enteric Viruses
      • 3.4.5 Industrial Microorganisms
    • 3.5 Molecular Diagnostics Forensics Testing Market
      • 3.5.1 Analysis by PCR-based DNA Typing
      • 3.5.2 Rapid Isolation of DNA for Restriction Fragment Length Polymorphism (RFLP) and PCR
      • 3.5.3 DNA for PCR-STR Typing
    • 3.6 Bioterrorism and Molecular Diagnostics
      • 3.6.1 Introduction
        • 3.6.1.1 Current Biological Threat Detection Systems
        • 3.6.1.2 Use of DNA Microarrays and Biochips for Gene Expression Profiles in BWAs
        • 3.6.1.3 Advantages and Disadvantages of Host Gene Expression Profiling as a Biothreat Detection
      • 3.6.2 Biological Warfare Agents (BWAs)
        • 3.6.2.1 Anthrax
        • 3.6.2.2 Botulinum Toxin
        • 3.6.2.3 Ricin
        • 3.6.2.4 IVD Industry and Bioterrorism Preparedness
        • 3.6.2.4.1 Brucellosis
        • 3.6.2.4.2 Cholera
        • 3.6.2.5 Rapid Lateral Flow Immunoassays
        • 3.6.2.6 Biosensors
      • 3.6.3 Anthrax in Clinical Samples
        • 3.6.3.1 Overview of Anthrax and its Infectivity
        • 3.6.3.2 Rapid Tests
    • 3.7 Cystic Fibrosis Testing
    • 3.8 Human Leukocyte Antigen (HLA) Sequencing-based Typing Kits
      • 3.8.1 Transplantation of Tissues
    • 3.9 Molecular Cytogenetic Testing
      • 3.9.1 Hereditary Hemochromatosis
      • 3.9.2 Apolipoprotein E (ApoE) Genotyping
      • 3.9.3 Fragile X Syndrome (FXS)
      • 3.9.4 Methylenetetrahydrofolate Reductase (MTHFR) Carrier Testing
    • 3.9 5 Other Genetic Testing Procedures
    • 3.10 Developments in DNA Biochips for Clinical Applications
      • 3.10.1 Product Analysis
      • 3.10.2 Breast Cancer DNA Arrays
      • 3.10.3 eSensor DNA Detection System
    • 3.11 Personalized Medicine, Pharmacogenomics and Molecular Diagnostics Testing
      • 3.11.1 Coumadin (Warfarin)
    • 3.12 Thrombic Disorders
    • 3.13 Respiratory Virus Panel
    • 3.14 HFE (Hemochromatosis)
    • 3.15 Lupus
    • 3.16 Down's Syndrome and Prenatal Screening
    • 3.17 Molecular Diagnostics Technology Platforms and their Impact on Personalized Medicine
  • 4. Trends in Molecular Diagnostics
    • 4.1 Pharmacogenomics
      • 4.1.1 The Market
        • 4.1.1.1 Oncology
        • 4.1.1.2 Toxicogenomics
      • 4.1.2 Market Influences and Forecast
    • 4.2 DNA Microarrays
      • 4.2.1 Techniques
      • 4.2.2 The Market
      • 4.2.3 Identification of Sequence SNPs
      • 4.2.4 Determining Gene Expression Levels
        • 4.2.4.1 Hybridization Tests
        • 4.2.4.2 Oligonucleotide Probes
      • 4.2.5 Molecular Diagnostics Entry into Point-of-Care (POC) Testing
    • 4.3 Emerging Markets of DNA Arrays
      • 4.3.1 Pharmacogenomics
      • 4.3.2 Adoption of Amplified Screening Technology
      • 4.3.3 Advances in Automated Testing
      • 4.3.4 Increased Focus on Safety of Blood Supply
      • 4.3.5 Development of Emerging Markets for NAT Technology
      • 4.3.6 Cancer
      • 4.3.7 Human Leukocyte Antigen (HLA) Typing
      • 4.3.8 Neonatal Screening
    • 4.4 Drivers and Restraints
    • 4.5 Market Forecast
    • 4.6 Business Trends in the Industry
      • 4.6.1 Molecular Diagnostics Industry Trends
        • 4.6.1.1 Adoption of Amplified Screening Technology
        • 4.6.1.2 Advances in Automated Testing
        • 4.6.1.3 Responsiveness to Newly Emerging Threats
        • 4.6.1.4 Increased Focus on Safety of Blood Supply
        • 4.6.1.5 Growth in Viral Load Testing
        • 4.6.1.6 Development of Emerging Markets for NAT Technology
        • 4.6.1.7 Improvements in Detection Technologies
        • 4.6.1.8 Use of Multiplex PCR Tests
      • 4.6.2 Pharmaceutical Industry Trends
      • 4.6.3 Acquisitions, License Agreements and Partnerships
      • 4.6.4 Ethical, Legal and Social Issues Related to the Use of Genetic Information
      • 4.6.5 Regulatory Issues
        • 4.6.5.1 U.S. Food and Drug Administration
        • 4.6.5.2 CLIA Regulations
        • 4.6.5.3 Clinical Laboratory Improvement Act (CLIA)
        • 4.6.5.4 State Licensing for Service Laboratories
        • 4.6.5.5 Multivariate Index Assays (IVDMIAs)
        • 4.6.5.6 510(k) Clearance
        • 4.6.5.6.1 Pre-Market Approval (PMA)
        • 4.6.5.7 PMAs
        • 4.6.5.8 ASRs
        • 4.6.5.9 Laboratory Developed Tests
        • 4.6.5.10 What Regulatory Guidance is needed for Companion Biomarkers?
        • 4.6.5.11 U.S. Patent and Trademark Office (USPTO)
        • 4.6.5.12 IRB Approval in Clinical Trials
        • 4.6.5.13 CE marking and the IVDD (European In Vitro Diagnostic Device Directive)
        • 4.6.5.14 De Novo Classification
        • 4.6.5.15 Research Use Only Reagents
      • 4.6.6 Reimbursement Issues and Billing Landscape for Molecular Diagnostics Testing
        • 4.6.6.1 Cystic Fibrosis
        • 4.6.6.2 Viral Load Testing
        • 4.6.6.3 NMP22
        • 4.6.6.4 Trends in Reimbursement Practice
        • 4.6.6.5 Medicare Reimbursement Threats
    • 4.7 Patent Protection and Intellectual Property Rights
      • 4.7.1 New Patents
      • 4.7.2 BRCA1 and BRCA2 Gene Patents
      • 4.7.3 Current Patent Disputes
    • 4.8 Micoarray Quality Control (MAQC)
  • 5. Molecular Diagnostics Automated Instrumentation Approved for Market by the FDA
    • 5.1 Gene Expression Profiling
    • 5.2 Proteomic Multiplex Assays
    • 5.3 Solution-Phase Multiplexing
    • 5.4 RNA Interference (RNAi)
      • 5.4.1 Role of RNAi in Drug Target Validation
      • 5.4.2 Other Companies involved in the RNAi Market
    • 5.5 DNA Tags
    • 5.6 Follow-on Optical Technologies
  • 6. Market Trends and Forecasts
    • 6.1 Market Dynamics
      • 6.1.1 Molecular Diagnostics Market Opportunities
      • 6.1.2 Market Forces
    • 6.2 Future Considerations for Molecular Diagnosis
    • 6.3 Role of Genomics in Transforming Pharmaceutical R&D
    • 6.4 Cancer Markers
    • 6.5 Cytology Markers
    • 6.6 RNA Detection
    • 6.7 Diagnosis of Inherited Disease
    • 6.8 Ethical Considerations
    • 6.9 NAT and Personalized Medicine
    • 6.10 Five Molecular Diagnostics Growth Areas
    • 6.11 Specific Commercial Nucleic Acid Probes
    • 6.12 Novel Amplification Techniques in the Market
    • 6.13 Ramification Amplification Method (RAM)
    • 6.14 Invader Assays/Third Wave Technologies (Hologic)
    • 6.15 Molecular Beacons
    • 6.16 Human Leukocyte Antigen (HLA) Sequencing-based Typing Kits
    • 6.17 Prenatal Diagnosis
    • 6.18 Newborn Screening
    • 6.19 NAT and Preventive Medicine: NAT-based Assays
    • 6.20 Prenatal and Pre-Implantation Diagnosis
    • 6.21 FISH-based Tests on Fetal Cells
    • 6.22 Companion Therapeutic/Diagnostic Approach
    • 6.23 Sample Preparation Market
    • 6.24 Emerging Amplification Techniques
      • 6.24.1 Gold Nanoparticle Molecular Probes
      • 6.24.2 Real-Time Microfluidic PCR Using Magnetic Affinity Beads
    • 6.25 ASRs (Analyte-Specific Reagents)
  • 7. Company Profiles
    • 7.1 Abbott Laboratories
    • 7.2 Adnavance Technologies, Inc.
    • 7.3 AdvanDx
    • 7.4 Agendia
    • 7.5 Agilent Technologies
    • 7.6 Asuragen
    • 7.7 Ambry Genetics
    • 7.8 American Diagnostica
    • 7.9 Applied Biosystems, Inc. (now Life Technologies)
    • 7.10 ARCA biopharma
    • 7.11 ArcticDx, Inc.
    • 7.12 Arcxis Biotechnologies
    • 7.13 Atlas Genetics
    • 7.14 Aureon Laboratories
    • 7.15 AutoGenomics, Inc.
    • 7.16 Beckman Coulter, Inc.
    • 7.17 Becton, Dickinson and Company
    • 7.18 BG Medicine
    • 7.19 Biocartis
    • 7.20 BioGenex Laboratories, Inc.
    • 7.21 Biohelix Corporation
    • 7.22 bioMerieux
    • 7.23 Bio-Rad Laboratories
    • 7.24 Biotage AB
    • 7.25 Biotest AG
    • 7.26 Caliper Life Sciences, Inc.
    • 7.27 Celera
    • 7.28 Cepheid
    • 7.29 CombiMatrix Corporation
    • 7.30 Cytocell Technologies Ltd.
    • 7.31 CytoCore, Inc.
    • 7.32 DiagnoCure, Inc.
    • 7.33 DxS (Acquired by QIAGEN)
    • 7.34 Enzo Biochem
    • 7.35 Epigenomics
    • 7.36 EraGen Biosciences
    • 7.37 Eurogentec
    • 7.38 EXACT Sciences Corporation
    • 7.39 Exiqon A/S
    • 7.40 GeneOhm Sciences
    • 7.41 Genera Biosystems
    • 7.42 Genzyme Corporation
    • 7.43 GenMark Diagnostics, Inc.
    • 7.44 Genomix Biotech
    • 7.45 Gen-Probe
    • 7.46 Gene Express
    • 7.47 Genomica
    • 7.48 Hologic
    • 7.49 Illumina, Inc.
    • 7.50 Innogenetics NV
    • 7.51 Invitrogen (Life Technologies)
    • 7.52 Life Technologies
    • 7.53 Luminex
    • 7.54 Inverness Medical Innovations
    • 7.55 Monogram Biosciences, Inc.
    • 7.56 Myconostica
    • 7.57 Nanogen
    • 7.58 Nanosphere
    • 7.59 NorDiag ASA
    • 7.60 PharMingen
    • 7.61 QIAGEN N.V.
    • 7.62 Roche Diagnostics
    • 7.63 SABiosciences Corporation
    • 7.64 Seegene
    • 7.65 Siemens Healthcare Diagnostics (Siemens)
    • 7.66 SIRS-Lab
    • 7.67 Source MDx
    • 7.68 Targeted Molecular Diagnostics
    • 7.69 Thermo Fisher Scientific
    • 7.70 Thorne Diagnostics
    • 7.71 TrimGen
    • 7.72 TrovaGene
    • 7.73 U.S. Genomics, Inc.
    • 7.74 Veredus Laboratories
    • 7.75 Veridex
  • 8. Market Overview
    • 8.1 Snapshot of Molecular Diagnostics Industry Structure
    • 8.2 Global Molecular Diagnostics Testing Market
    • 8.3 U.S. Molecular Diagnostics Testing Market
    • 8.4 European Molecular Diagnostics Market
    • 8.5 Japanese Molecular Diagnostics Testing Market
    • 8.6 Overview of the European Molecular Diagnostics Country Markets
      • 8.6.1 France
      • 8.6.2 Germany
      • 8.6.3 U.K.
      • 8.6.4 Italy
      • 8.6.5 Spain
    • 8.7 Strategic Assessment and Business Development in the Molecular Diagnostics Sector
      • 8.7.1 Industry Background
      • 8.7.2 Competition
      • 8.7.3 Business Strategy
      • 8.7.4 Corporate Examples
        • 8.7.4.1 Gen-Probe
        • 8.7.4.2 Osmetech
        • 8.7.4.3 Combimatrix
        • 8.7.4.4 Sekisui Chemical Co. Ltd.
        • 8.7.4.5 Myriad Genetics
        • 8.7.4.6 Luminex
      • 8.7.5 IVD Manufacturers' Goals in Detection Technology Development
        • 8.7.5.1 New Developments in Molecular Diagnostic Markers are driven by Corporate Joint Ventures
        • 8.7.5.2 Factors for Growth in Molecular Diagnostics
        • 8.7.5.3 How has the IVD Industry Changed?
        • 8.7.5.4 What are the Challenges for the Future?
        • 8.7.5.5 What New Trends are in the Future?
        • 8.7.5.5.1 Market and Technology Trends
        • 8.7.5.5.1.1 Market Trends
        • 8.7.5.5.1.2 Technology Trends
        • 8.7.5.5.1.3 Strategic Recommendations
  • INDEX OF FIGURES
    • Figure 2.1: Segment of Double-stranded DNA Showing the Base-Pair Relationship
    • Figure 3.1: Overall Structure of Nucleic Acid Testing Market
    • Figure 3.2: Global Market for Molecular Diagnostics Testing, 2010
    • Figure 3.3: Share of Molecular Diagnostics Testing by Testing Type, 2009
    • Figure 3.4: Key Players Market Share in Global Molecular Diagnostics Testing Markets
    • Figure 3.5: Revenue Mix from BioChips
    • Figure 3.6: Global Revenue Forecast for Molecular Diagnostics Testing for Infectious Disease, 2009-2016
    • Figure 3.7: Global Market Revenue Share Forecasts for Molecular Diagnostics Infectious Disease Testing Markets by Region, 2009 and 2016
    • Figure 3.8: Forecast for Total Global Infectious Disease Molecular Diagnostics Markets, 2016
    • Figure 3.9: Forecast for Total U.S. Infectious Disease Molecular Diagnostics Markets, 2016
    • Figure 3.10: Key Players Market Share in Global Molecular Diagnostics Infectious Disease Testing Markets
    • Figure 3.11: Estimated Market Forecast for Global HIV Molecular Diagnostic Testing, 2011-2016
    • Figure 3.12: Markers of Acute HBV Infection as a Function of Time after Exposure to Infection
    • Figure 3.13: Primary Causes of Chronic Liver Disease
    • Figure 3.14: Markers of Acute HCV Infection as a Function of Time after Exposure to Infection
    • Figure 3.15: U.S. Market Share for Molecular Diagnostic HPV Testing, 2010
    • Figure 3.16: Analysis of Cancer Tissue by Microarray
    • Figure 3.17: Number of Genomic Health Oncotype DX Tests Performed, 1991-2006
    • Figure 3.18: U.S. Total Infectious Disease Molecular Diagnostics Markets, 2009
    • Figure 3.19: Estimated Market for Global Blood Screening Product Sales, 2007-2016
    • Figure 3.20: Blood Screening Market Share, 2010
    • Figure 3.21: Bacillus anthracis
    • Figure 4.1: Reimbursement for Diagnostics in Healthcare Decision Making
    • Figure 7.1: Gen-Probe Projected R&D Expenditures
    • Figure 8.1: Molecular Diagnostics Market Segmentation by Testing Type
    • Figure 8.2: Molecular Diagnostics Market Segmentation by Technology
    • Figure 8.3: Global Market for Molecular Diagnostics, 2002-2016
    • Figure 8.4: Global Distribution of Molecular Diagnostics Testing by Geographic Region, 2010
  • INDEX OF TABLES
    • Table 2.1: Key Assay Technologies for Molecular Diagnostics
    • Table 2.2: Emerging Molecular Diagnostic Technologies
    • Table 2.3: Companies involved in Next Generation Sequencing Technology
    • Table 3.1: Applications of Molecular Diagnostics Technology Platforms
    • Table 3.2: Global Market for Molecular Diagnostics Testing, 2000-2016
    • Table 3.3: U.S. Market for Molecular Diagnostics Testing, 2004-2016
    • Table 3.4: Summary of Molecular Diagnostics Testing Clinical Focus and Detection
    • Table 3.5: Share of Molecular Diagnostics Testing by Testing Type, 2009
    • Table 3.6: Key Players and Market Share in Global Molecular Diagnostics Testing Market
    • Table 3.7: Revenue Model for Molecular Diagnostics Testing
    • Table 3.8: Annual U.S. Market for DNA Probe Diagnostics, 1998-2012
    • Table 3.9: Annual Global Market for DNA Probe Diagnostics, 1998-2010
    • Table 3.10: Roche PCR Licenses
    • Table 3.11: Companies Marketing Products Using DNA Probes
    • Table 3.12: Companies Marketing Multiple Products in Molecular Diagnostics Sector
    • Table 3.13: Global Sales of DNA Probe Kits, 1998-2009
    • Table 3.14: Companies Marketing DNA Detection Platforms
    • Table 3.15: Companies Marketing Genotyping Technologies
    • Table 3.16: Companies Marketing Clinical Genotyping Technologies
    • Table 3.17: Global Revenues and Forecast for Molecular Diagnostics Testing for Infectious Disease, 2009-2016
    • Table 3.18: Molecular Diagnostic Markets for Infectious Disease Testing, 2010
    • Table 3.19: Molecular Diagnostic Markets for Infectious Disease Testing, 2016
    • Table 3.20: Key Players and Market Share in Global Molecular Diagnostics Infectious Disease Testing Market
    • Table 3.21: Commercially Available Molecular Diagnostic Products for HIV Assay
    • Table 3.22: Summary of Assays for HIV Viral Load Testing
    • Table 3.23: Global Market for Molecular Diagnostic HIV Testing, 2007-2010
    • Table 3.24: U.S. Market for HIV Molecular Diagnostic Testing, 2007-2010
    • Table 3.25: Global Market Forecast for Molecular Diagnostic HIV Diagnostic Testing, 2011-2016
    • Table 3.26: U.S. Market Forecast for Molecular Diagnostic HIV Diagnostic Testing, 2011-2016
    • Table 3.27: Markers for Diagnosis of HBV Infections
    • Table 3.28: Recommendations for HBV Diagnostic Testing
    • Table 3.29: Lower Detection Limits of HBV DNA Assays
    • Table 3.30: Summary of Molecular Diagnostic Assays for Testing HBV
    • Table 3.31: Global Market for HBV Diagnostic Testing, 2000-2010
    • Table 3.32: U.S. Market for HBV Diagnostic Testing, 2000-2010
    • Table 3.33: Global Market Forecast for HBV Diagnostic Testing, 2011-2016
    • Table 3.34: U.S. Market Forecast for HBV Diagnostic Testing, 2011-2016
    • Table 3.35: Recommendations for HCV Diagnostic Testing
    • Table 3.36: Important HCV Statistics
    • Table 3.37: Commercially Available Molecular Diagnostic Products for HCV Assay
    • Table 3.38: Global Market for DNA HCV Diagnostic Testing, 2005-2010
    • Table 3.39: U.S. Market for DNA HCV Diagnostic Testing, 2005-2010
    • Table 3.40: Global Market Forecast for NAT HCV Diagnostic Testing, 2011-2016
    • Table 3.41: U.S. Market Forecast for NAT HCV Diagnostic Testing, 2011-2016
    • Table 3.42: Global Market for DNA HAV Diagnostic Testing, 2000-2008
    • Table 3.43: U.S. Market for DNA HAV Diagnostic Testing, 2000-2008
    • Table 3.44: Global Market for DNA HBV Diagnostic Testing, 2000-2008
    • Table 3.45: U.S. Market for DNA HBV Diagnostic Testing, 2000-2008
    • Table 3.46: Global Market for DNA HCV Diagnostic Testing, 2000-2008
    • Table 3.47: U.S. Market for DNA HCV Diagnostic Testing, 2000-2008
    • Table 3.48: Commercially Available Molecular Diagnostic Products for HPV Assay
    • Table 3.49: Major Companies Marketing HPV Molecular Diagnostic Tests: Market Size and Share, 2010
    • Table 3.50: Global Market for HPV Molecular Diagnostic Testing, 2007-2010
    • Table 3.51: U.S. Market for HPV Diagnostic Testing, 2007-2010
    • Table 3.52: Global Market Forecast for HPV Molecular Diagnostic Testing, 2011-2016
    • Table 3.53: U.S. Market Forecast for HPV Diagnostic Testing, 2011-2016
    • Table 3.54: Commercially Available Molecular Diagnostic Products for Influenza Assay
    • Table 3.55: Global Market for Molecular Influenza Diagnostic Testing, 2007-2010
    • Table 3.56: U.S. Market for DNA Influenza Diagnostic Testing, 2007-2010
    • Table 3.57: Global Market Forecast for Influenza Molecular Diagnostic Testing, 2010-2016
    • Table 3.58: U.S. Market Forecast for Influenza Molecular Diagnostic Testing, 2010-2016
    • Table 3.59: Global Market for Molecular Diagnostics Cancer Testing, 2008-2016
    • Table 3.60: Leading Segments of the Molecular Diagnostic Testing Market
    • Table 3.61: KRAS Assays by Analytical Type
    • Table 3.62: KRAS Mutation Assay from Exiqon Diagnostics
    • Table 3.63: Players in the Breast Cancer Molecular Diagnostic Space
    • Table 3.64: U.S. Molecular Diagnostic Markets for Infectious Disease Testing, 2009
    • Table 3.65: Commercially Available Molecular Diagnostic Products for Chlamydia Assay
    • Table 3.66: Global Market for Molecular Diagnostic Chlamydia/Gonorrhea Diagnostic Testing, 2000-2010
    • Table 3.67: U.S. Market for Chlamydia/Gonorrhea Diagnostic Testing, 2000-2010
    • Table 3.68: Global Market Forecast for Chlamydia/Gonorrhea Diagnostic Testing, 2011-2016
    • Table 3.69: U.S. Market Forecast for Chlamydia/Gonorrhea Diagnostic Testing, 2010-2016
    • Table 3.70: CPT Code1 Description National Limitation Amount
    • Table 3.71: Global Market for MD TB Diagnostic Testing, 2005-2010
    • Table 3.72: U.S. Market for MD TB Diagnostic Testing, 2005-2010
    • Table 3.73: Global Market for DNA Group B Streptococcus Diagnostic Testing, 2000-2009
    • Table 3.74: U.S. Market for DNA Group B Streptococcus Diagnostic Testing, 2000-2009
    • Table 3.75: Gen-Probe Clinical Diagnostic Products for the Detection of Non-Viral Micro-Organisms
    • Table 3.76: Commercially Available Molecular Diagnostic Products for MRSA Assay
    • Table 3.77: Global Market for MRSA Diagnostic Testing, 2005-2010
    • Table 3.78: U.S. Market for MRSA Diagnostic Testing, 2005-2010
    • Table 3.79: Global Market Forecast for MD MRSA Diagnostic Testing, 2011-2016
    • Table 3.80: U.S. Market Forecast for MD MRSA Diagnostic Testing, 2011-2016
    • Table 3.81: Commercially Available Molecular Diagnostic Products for VRE Assay
    • Table 3.82: Global Market for VRE Diagnostic Testing, 2005-2010
    • Table 3.83: U.S. Market for VRE Diagnostic Testing, 2005-2010
    • Table 3.84: Global Market Forecast for MD VRE Diagnostic Testing, 2011-2016
    • Table 3.85: U.S. Market for MD VRE Diagnostic Testing, 2011-2016
    • Table 3.86: Global Market for Blood Screening Product Sales, 2007-2016
    • Table 3.87: Blood Screening Molecular Diagnostics Market: Market Drivers Ranked in Order of Impact
    • Table 3.88: Blood Screening Molecular Diagnostics Market: Market Restraints Ranked in Order of Impact
    • Table 3.89: Drivers of the Genetic Analysis Market
    • Table 3.90: Leading Players in the SNP Genotyping Space
    • Table 3.91: Global Market for SNP and Genotyping, 2009-2015
    • Table 3.92: Instrumentation
    • Table 3.93: Consumables
    • Table 3.94: DNA Analysis Market Competitors
    • Table 3.95: Leading Companies in Medical Utility of SNPs
    • Table 3.96: Competitors in the Field of Identity, Family and Paternity Testing
    • Table 3.97: Competitors in the Field of Forensic Testing
    • Table 3.98: U.S. Market for Food-Screening Diagnostic Testing Using MD Techniques, 2000-2016
    • Table 3.99: Molecular Diagnostics Methods for Detection of Salmonella in Food
    • Table 3.100: U.S. Market for Forensic Diagnostics Testing, 2000-2016
    • Table 3.101: Barriers for Biologics Warfare Monitoring Systems
    • Table 3.102: U.S. Market for Biological Threat Detection Testing, 2000-2010
    • Table 3.103: Technical Problems for PCR Assays for Pathogen Genotyping and Detection
    • Table 3.104: Biological Warfare Agents Identified by PCR Methods
    • Table 3.105: Companies Developing Detection Devices for Biological Warfare Agents
    • Table 3.106: Variation of CF Carrier Risks by Ethnic Group
    • Table 3.107: Reasons for CF Testing
    • Table 3.108: Variation of CF Detection Rates by Ethnic Background
    • Table 3.109: Global Market for CF Diagnostic Testing, 2000-2008
    • Table 3.110: U.S. Market for CF Diagnostic Testing, 2000-2008
    • Table 3.111: Projected Global Market for CF Diagnostic Testing, 2009-2013
    • Table 3.112: Projected U.S. Market for CF Diagnostic Testing, 2009-2013
    • Table 3.113: Commercial CF-Screening Products
    • Table 3.114: CF Screening Technology Summary
    • Table 3.115: U.S. Market for HLA Type Testing, 2000-2009
    • Table 3.116: Competitors in HLA Testing
    • Table 3.117: Carrier Rates of Common HFE Mutations in Caucasians
    • Table 3.118: Results and Diagnosis for Fragile X Syndrome
    • Table 3.119: Other Genetic Testing Procedures by Molecular Diagnostics
    • Table 3.120: DNA Chip Market Drivers and Restraints
    • Table 3.121: DNA Chip Major Players
    • Table 3.122: Applications of DNA Biochips
    • Table 3.123: Technology Trends in the DNA Microarray Market
    • Table 3.124: Molecular Diagnostic Personalized Medicine Tests
    • Table 3.125: Global Revenue Forecasts for Prenatal and Newborn Testing Segment, 2007-2015
    • Table 3.126: Various Molecular Diagnostics Technologies: Timeline for Impact
    • Table 3.127: Various Molecular Diagnostics Technologies: Impact on Different Therapeutic Areas in Personalized Medicine
    • Table 3.128: Various Molecular Diagnostics Technologies: Technical Challenges in the Deployment for Personalized Medicine
    • Table 4.1: DNA-Sequencing Molecular Diagnostics Market Players
    • Table 4.2: U.S. Market for DNA Chips, 2000-2015
    • Table 4.3: Affymetrix DNA Analysis Products
    • Table 4.4: PCR Segmentation by Sector
    • Table 4.5: Impediments to Incorporating Promising Molecular Tests into Clinical Practice
    • Table 4.6: Largest Market Opportunities in PCR Testing
    • Table 4.7: PCR Real-Time Applications
    • Table 4.8: Advantages of Using Real-Time PCR
    • Table 4.9: Pharmaceutical Company Challenges
    • Table 4.10: Molecular Diagnostic Sector Acquisitions, Agreements and Partnerships
    • Table 4.11: Regulatory Rules that Affect the Ability of a Diagnostic Testing Reagent Company to Conduct Business
    • Table 4.12: Strengths of the 510k Process
    • Table 4.13.: Focus Areas for the FDA Critical Path Initiative
    • Table 4.14: Medicare Pricing Methods
    • Table 4.15: Factors Affecting Third-Party Reimbursement for Molecular Diagnostic Tests
    • Table 4.16: Documents for Protecting Intellectual Property Rights
    • Table 4.17: Recent Patents Related to PCR, Nucleic Acid Amplification, and Sample Prep
    • Table 5.1: Molecular Diagnostic High-throughput Automated Testing Systems
    • Table 6.1: Five Molecular Diagnostics Growth Areas
    • Table 6.2: Limitations of Nucleic Acid Chip Probes
    • Table 6.3: Companies Licensed to Sell Custom Molecular Beacon Probes
    • Table 6.4: U.S. Sample Preparation Market, 2005-2012
    • Table 7.1: Products Marketed by Abbott in the Diagnostics Market
    • Table 7.2: Gen-Probe Key Acquisitions
    • Table 7.3: Roche Diagnostics Key Products
    • Table 7.4: Sales by Region
    • Table 7.5: Sales by Business Area
    • Table 7.6: Product Line Sales
    • Table 7.7: Growth Drivers
    • Table 8.1: Number of Molecular Diagnostics Tests in the U.S., 2008-2015
    • Table 8.2: Global Molecular Diagnostics Testing Revenues, 2000-2016
    • Table 8.3: Global Distribution of Molecular Diagnostics Testing by Geographic Region, 2010
    • Table 8.4: U.S. Molecular Diagnostics Testing Market, 2004-2016
    • Table 8.5: European Molecular Diagnostics Testing Market, 2005-2016
    • Table 8.6: Japanese Molecular Diagnostics Testing Market, 2005-2016
    • Table 8.7: Molecular Diagnostics Market: Market Drivers Ranked in Order of Impact
    • Table 8.8: Molecular Diagnostics Market: Market Restraints Ranked in Order of Impact
    • Table 8.9: Large General Diagnostic Lab Services
    • Table 8.10: Small Specialized Diagnostic Lab Services
    • Table 8.11: MDx Sector Leaders
    • Table 8.12: Point-of-Care MDx Leaders
    • Table 8.13: Pure Play MDx Companies
    • Table 8.14: Array Platforms
    • Table 8.15: Molecular Diagnostic Testing Market Trends
    • Table 8.16: Molecular Diagnostic Testing Technology Trends
    • Table 8.17: Molecular Diagnostics Market: Strategic Recommendations on MD Sector Business Functions